Oncotarget

Vol 1, No 1

May 2010

View Archive »

Order a Reprint

Editorial

Introducing Oncotarget

Introducing Oncotarget

https://doi.org/10.18632/oncotarget.101

Mikhail Blagosklonny,  and Andrei Gudkov
2
PDF  |  Order a Reprint

Commentaries

Shape-shifting and tumor suppression by PLZF

Shape-shifting and tumor suppression by PLZF

https://doi.org/10.18632/oncotarget.102

Robin M. Hobbs,  and Pier Paolo Pandolfi
3-5
PDF  |  Order a Reprint

Reviews

Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors

Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors

https://doi.org/10.18632/oncotarget.103

Stefan Duensing,  and Anette Duensing
6-8
Abstract  |  PDF  |  Order a Reprint

Research Papers

Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation

Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation

https://doi.org/10.18632/oncotarget.104

Jin Shi, Minghao Sun,  and Peter K. Vogt
9-21
Abstract  |  PDF  |  Order a Reprint

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

https://doi.org/10.18632/oncotarget.105

Lei Shi, Siqing Wang, Maurizio Zangari, Hongwei Xu, Thai M. Cao, Chunjiao Xu, Yong Wu, Fang Xiao, Yinghong Liu, Ye Yang, Mohamed Salama, Guiyuan Li, Guido Tricot,  and Fenghuang Zhan
22-33
Abstract  |  PDF  |  Order a Reprint

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

https://doi.org/10.18632/oncotarget.106

Emmanuel Raffoux, Audrey Cras, Christian Recher, Pierre-Yves Boëlle, Adrienne de Labarthe, Pascal Turlure, Jean-Pierre Marolleau, Oumedaly Reman, Claude Gardin, Maud Victor, Sébastien Maury, Philippe Rousselot, Jean-Valère Malfuson, Odile Maarek, Marie-Thérèse Daniel, Pierre Fenaux, Laurent Degos, Christine Chomienne, Sylvie Chevret,  and Hervé Dombret
34-42
Abstract  |  PDF  |  Order a Reprint

Research Perspectives

The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword

The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword

https://doi.org/10.18632/oncotarget.107

Michael Hölzel, Kaspar Burger, Bastian Mühl, Mathias Orban, Markus Kellner,  and Dirk Eick
43-47
Abstract  |  PDF  |  Order a Reprint

ID4: a new player in the cancer arena

ID4: a new player in the cancer arena

https://doi.org/10.18632/oncotarget.108

Stefania Dell’Orso, Federica Ganci, Sabrina Strano, Giovanni Blandino,  and Blandino Fontemaggi
48-58
Abstract  |  PDF  |  Order a Reprint

A critical role for the NFkB pathway in multiple myeloma

A critical role for the NFkB pathway in multiple myeloma

https://doi.org/10.18632/oncotarget.109

Yulia Demchenko,  and W. Michael Kuehl
59-68
Abstract  |  PDF  |  Order a Reprint

Targeting TOR dependence in cancer

Targeting TOR dependence in cancer

https://doi.org/10.18632/oncotarget.110

Matthew R. Janes,  and David A. Fruman
69-76
Abstract  |  PDF  |  Order a Reprint


Copyright © 2018 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC